David has made over 2 trades of the NovoCure Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 539,375 units of NVCR stock worth $10,000,013 on 17 April 2017.
The largest trade he's ever made was buying 539,375 units of NovoCure Ltd stock on 17 April 2017 worth over $10,000,013. On average, David trades about 67,422 units every 0 days since 2017. As of 17 April 2017 he still owns at least 539,375 units of NovoCure Ltd stock.
You can see the complete history of David Hung stock trades at the bottom of the page.
Dr. David T. Hung M.D. serves as Independent Director of the Company. Dr. Hung is the founder, president, chief executive officer and director of Nuvation Bio, Inc., a biotech company, since June 2019. Dr. Hung was previously chief executive officer and a director of Axovant Sciences, Inc., a pharmaceutical company, from April 2017 to February 2018. As a founder of Medivation Inc. (“Medivation”), a biopharmaceutical company, he served as president, chief executive officer and a director of Medivation from 2004 to 2016. From 1998 until 2001, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as chief scientific officer from 1998 to 1999 and as president and chief executive officer and director from 1999 to 2001. He has been Director of ARYA Sciences Acquisition Corp. since September 2018 and director of Establishment Labs Holdings Inc. since February 2016. Formerly a director of Axovant Sciences, Inc. from April 2017 to February 2018 and of Medivation from 2004 to 2016. He holds A.B. in Biology, Harvard College; M.D., University of California, San Francisco, School of Medicine.
As the Independent Director of NovoCure Ltd, the total compensation of David Hung at NovoCure Ltd is $397,470. There are 15 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.
David Hung is 62, he's been the Independent Director of NovoCure Ltd since 2018. There are 5 older and 17 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.
David's mailing address filed with the SEC is C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE, PA, 19087.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ... и Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: